







an Open Access Journal by MDPI

New Biomarkers in Cancers (Volume II)

Guest Editor:

Prof. Dr. Jochen Sven Utikal

1. Skin Cancer Unit, German Cancer Research Center (DKFZ), 69121 Heidelberg, Germany 2. Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, 68167 Mannheim, Germany

Deadline for manuscript submissions:

15 December 2024

Message from the Guest Editor

Dear Colleagues,

This collection is the second edition of the previous one "New Biomarkers in Cancers" (https://www.mdpi.com/journal/cancers/special_issues/NBCance

In recent years, several new therapies have been approved for different cancer entities. Due to these new therapeutic options, physicians are confronted with new challenges, such as monitoring progression and stratifying patients for appropriate treatments.

Novel analytical techniques using body fluids, such as blood, and tumor tissue have identified numerous possible biomarkers

In this Special Issue, we will publish reviews and original research that provide new insights into the role of predictive and prognostic tumor biomarkers. Novel insights into tumor biomarkers are particularly welcome.

Prof. Dr. Jochen Sven Utikal Guest Editor













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us